TI
CRVS icon

Trexquant Investment’s Corvus Pharmaceuticals CRVS Stock Holding History

Trexquant Investment’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.43M Buy
+296,347
New +$4.11M 0.03% 808
2025
Q4 		– Sell
-12,226
Closed -$90.1K – 1634
2025
Q3 		$90.1K Buy
+12,226
New +$62.6K ﹤0.01% 1538
2018
Q4 		– Sell
-12,483
Closed -$107K – 1070
2018
Q3 		$107K Buy
+12,483
New +$125K 0.01% 892
2018
Q1 		– Sell
-17,971
Closed -$186K – 1120
2017
Q4 		$186K Buy
+17,971
New +$230K 0.02% 954

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Trexquant Investment's CRVS Position: Q2 2026 in Review

Trexquant Investment opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 296,347 shares worth $4.43M. The stake represents 0.03% of the portfolio and ranks #808 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in CRVS as recently as Q3 2025.

Trexquant Investment first reported a position in CRVS in Q4 2017 and has held it in 4 quarters since. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Trexquant Investment held 296,347 shares of Corvus Pharmaceuticals worth $4.43M as of Q2 2026.
  • Corvus Pharmaceuticals was a new Trexquant Investment position in Q2 2026.
  • Corvus Pharmaceuticals made up 0.03% of Trexquant Investment's portfolio in Q2 2026, its #808 holding.
  • Trexquant Investment first reported a position in Corvus Pharmaceuticals in Q4 2017 and has held it in 4 quarters since.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.